COMMUNIQUÉS West-GlobeNewswire

Dogecoin Cash, Inc. Announces PrestoDoctor’s Expansion into Three New Markets
05/08/2025
Arizona, Massachusetts, and Virginia Mesquite, NV, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dogecoin Cash, Inc. (OTCQB: DOGP), a publicly traded company focused on telehealth services and blockchain-based innovation, today [...]
Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress
05/08/2025
Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2 nd generation antisense oligonucleotide (ASO), in healthy volunteers demonstrated favorable pharmacokinetic (PK) characteristics AIC468 [...]
Amneal Reports Second Quarter 2025 Financial Results
05/08/2025
‒ Q2 2025 Net Revenue of $725 million ; GAAP Net Income of $22 million ; Diluted Income per Share of $0.07 ‒ ‒ Adjusted EBITDA of $184 million ; Adjusted Diluted EPS of $0.25 ‒ ‒ Raising 2025 Full Year Guidance ‒ ‒ Full [...]
Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts
05/08/2025
Nociscan YOY scan volume increased 132% from Q2 2024 to Q2 2025 fueled by new physician adoption and insurance company coverage in the UK Company has achieved two consecutive quarters of scan volume growth for the first [...]
Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference
05/08/2025
BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, [...]
CorVel Announces Revenues and Earnings
05/08/2025
FORT WORTH, Texas, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended June 30, 2025. Revenues for the quarter were $235 million, an increase from $212 million [...]
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
05/08/2025
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE [...]
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
05/08/2025
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash and cash equivalents [...]
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
05/08/2025
Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in [...]
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates
05/08/2025
Second -quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 million As of June 30, 2025 , more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, 2045 Announced [...]
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
05/08/2025
FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical [...]
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
05/08/2025
SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Envision Pharma Group appoints Tom Langan as Chief Executive Officer
05/08/2025
Envision Pharma Group appoints Tom Langan as Chief Executive Officer Leading industry executive with 30 years’ of experience providing technology-enabled solutions to life sciences companies Fairfield, Connecticut, USA [...]
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
05/08/2025
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development ACI- [...]
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
05/08/2025
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug [...]
Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance
05/08/2025
Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance Schlieren (Zürich), Switzerland, August 5, 2025 – Kuros Biosciences (“ [...]
Nicox annonce l’initiation par son partenaire Kowa d’un essai clinique de Phase 3 pour NCX 470 au Japon
05/08/2025
Communiqué de presse Nicox annonce l’initiation par son partenaire Kowa d’un essai clinique de Phase 3 pour NCX 470 au Japon Kowa, le partenaire exclusif de Nicox au Japon, a initié un essai clinique de sécurité de [...]
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
05/08/2025
Press Release Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in [...]
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
05/08/2025
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug [...]

Pages